Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s
In this episode of GEN 's Touching Base , editors discuss business news from Axiom and Latigo, and science updates on the potential roots of fibromyalgia and base editing for Huntington’s disease. The post Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s appeared first on GEN - Genetic Engineering and Biotechnology News .
In this week's episode of Touching Base, Axiom Biosciences announced its intention to go public on the Hong Kong Exchange instead of a U.S. market. The company's CEO Alex Philippidis discussed the rationale behind this strategic move in the StockWatch segment. Meanwhile, Latigo Therapeutics revealed positive Phase IIb data for its non-opioid acute pain candidate, generating excitement for the planned IPO the company has scheduled soon.
In the realm of scientific research, a study published in Genetic Engineering and Biotechnology News (GEN) identified genetic risk factors for fibromyalgia syndrome. The findings further revealed connections between fibromyalgia and other neurodegenerative, autoimmune, and metabolic diseases. Additionally, a base editing strategy demonstrated promising results in alleviating Huntington's disease in mice, as reported in another GEN article.
These discoveries add to the ongoing efforts in developing innovative therapies for neurological disorders and chronic pain management.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
